and 370 with negative PCT underwent thyroid surgery. MTC was histologically confirmed in all patients with positive PCT but not found in patients with negative PCT. Serum PCT levels were significantly higher in patients with MTC (median 0.64 lg/L, range 0.16-12.9 lg/L) than in those without (median 0.075 lg/ L, range 0.075-0.16 lg/L; P < .0001). ROC curves were plotted to calculate the optimal PCT value separating patients with MTC from those without. The best cutoff was 0.155 lg/L with sensitivity, specificity, positive and negative predictive values as well as accuracy of 100%, 99.7%, 91.7%, 100% and 99.7%, respectively. Positive and negative likelihood ratios were 329 and zero, respectively. Conclusions: Measurement of PCT is a sensitive and accurate method for detecting MTC in patients with thyroid nodules and can thus be a reliable alternative to CT measurement.
| INTRODUCTION
Medullary thyroid cancer (MTC) harbours from the thyroid parafollicular C cells and accounts for~3% to 5% of all thyroid carcinomas. 1 The majority of MTCs are sporadic and generally present as a thyroid nodule. At the time of diagnosis, cervical lymph node and distant metastases are present in up to 50% and 10% of patients. 1, 2 Calcitonin (CT) is a polypeptide hormone consisting of 32 amino acids mainly produced by the C cells. The measurement of CT concentrations in blood reflects the mass and activity of the C cells; it is generally performed using immunoassay-based methods. 3 There is a considerable body of evidence that the measurement of serum CT concentrations in patients with thyroid nodules can lead to an earlier diagnosis of MTC than the exclusive use of imaging procedures and/or fine-needle aspiration cytology (FNAC). [4] [5] [6] [7] However, there is some controversy regarding the screening of thyroid nodules with CT measurements as to whether this is a cost-effective exercise in terms of reducing deaths. 8, 9 In addition, different analytical, physiological, pharmacological and pathological factors may significantly reduce the specificity and overall accuracy of serum CT measurement. 3 Due to the influence of these factors, there is a high variability in assay-dependent and gender-dependent cutoffs used to discriminate between MTC, C-cell hyperplasia (CCH) and healthy C cells. 10 Additionally, CT is prone to in vitro decay at room temperature which makes rapid centrifugation and storage at À20°C of samples mandatory. 11, 12 All in all, pros and cons of using CT to screen patients carrying thyroid nodules for MTC are differently balanced in currently available clinical guidelines: the ETA consensus report published in 2006 clearly states that routine measurement of CT should be applied in the management of thyroid nodule cases, as it is more sensitive than fine-needle cytology. 13 Besides, the more recent AACE, AME and ETA's common document declared that routine measurement of basal CT may be useful and strongly recommended its measurement in certain high-risk groups.
14 Finally, the ATA's guidelines panel decided to not recommend either for or against routine measurement of serum CT in patients with thyroid nodules 8 but recommend that physicians decide whether the technique is useful in the management of patients in their clinic. 9 If CT screening is adopted it should be noted that depending on the assay used, 56%-88% of subjects without thyroid disease usually show a CT level below the functional sensitivity, while 3%-10% have CT levels >10 pg/mL. 15, 16 A CT stimulation test using pentagastrin or calcium should be performed to increase sensitivity and specificity of basal CT measurement and to avoid unnecessary thyroidectomies. 24 In a prospective study from our group, 25 CT was measured in a consecutive series of 1236 patients carrying thyroid nodules, and 14 cases displayed increased CT levels (ie, >10 lg/L) and were selected for a pentagastrin stimulation test. Upon histology, 2 MTCs were recorded, and they had basal CT >100 ng/L and PCT of >0.1 lg/L. The main results of that study were that basal and pentagastrin-stimulated CT had some false-positive results, whereas all of the patients without MTC had undetectable levels of both basal and stimulated PCT with a 100% positive predictive value (PPV) and a 100% negative predictive value (NPV), respectively. Thus, a negative basal PCT excluded MTC without the need for additional stimulation tests. Such data were recently corroborated by Lim et al. 26 They assessed 476 serum samples referred for CT measurements and evaluated the role of PCT in predicting negative CT results. In summary, the NPVs of PCT ranged from 95.4% to 100%. Finally, Machens et al 27 compared preoperative PCT and CT in a series of 112 consecutive patients with previously untreated MTC. Receiver operating characteristics (ROC) analyses revealed similar diagnostic accuracy for PCT and CT for primary tumours, extrathyroid extension, number of lymph nodes involved and distant metastasis. Among 112 cases, 107 had PCT levels of more than 0.1 lg/L, with a sensitivity of 95.5%. The remaining 5 patients had a micro-MTC with a mean diameter of 2 mm (range 0.4-3.5 mm). Of interest, PCT levels were correlated with the number of lymph nodes involved and the extent of distant metastatic disease. As the PCT levels increased, the biochemical cure rates declined. On the whole, the above-mentioned study results suggested that PCT could be a new standard of care in the management of MTC and, at minimum, is a useful complementary biomarker to exclude MTC in patients with suspicious thyroid nodules or suggestive symptoms. 28 This study was undertaken to prospectively evaluate the diagnostic performance of PCT as the first-line biomarker to screen patients with thyroid nodules for medullary thyroid carcinoma.
| MATERIALS AND METHODS

| Work-up of thyroid nodules
As per our standard operative procedures patients with thyroid nodules undergo clinical examination, thyroid ultrasound and measurement of thyroid-stimulating hormone (TSH; with additional measurement of free-thyroxine [fT4] levels when abnormal). 99m Tc-pertechnetate scintigraphy was performed in patients with nodules larger than 10 mm and/or low TSH levels. Autonomously functioning nodules were treated accordingly or monitored at the discretion of the attending physician. Based on criteria for thyroid ultrasound proposed by the American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, European Thyroid Association (AACE/AME/ETA) guidelines, 14 
| Study design and reference standard
For the purpose of this study, serum PCT was measured in patients with thyroid nodules referred to our centre between 
| Statistical analysis
For the convenience of data analyses, values of PCT and CT below the functional sensitivity were considered as equal to the functional sensitivity of assay methods (ie, CT and PCT values below 5 ng/L and 0.075 lg/L were included in the analysis as 5 ng/L and 0.075 lg/L, respectively). Categorical data were analysed by chisquare testing or Z test for proportions while continuous data were analysed by parametric or nonparametric tests for differences in means or medians, respectively, depending on the normality of distribution. Continuous variables were dichotomized by receiver operating characteristics (ROC) curve analysis using the maximum value of Youden's index (J) as the most accurate cut-off point. The predictivity tests, that is sensitivity, specificity, PPV, NPV and accuracy, were calculated according to Galen and Gambino. 34 All statistical tests were performed by GRAPH-PAD PRISM version 7 (GraphPad Software Inc., La Jolla, CA, USA).
| RESULTS
The initial series included 3730 consecutive adult patients (2672 females and 1058 males, mean age 52 AE 18 years). After exclusion of 24 patients with a personal or family history of MTC or multiple endocrine neoplasia, 958 patients with autonomously functioning nodules, 43 patients with severe systemic inflammation (n = 34), infection (n = 7) and sepsis (n = 2), 2705 patients were FTC, follicular thyroid carcinoma; PCT, procalcitonin; PDTC, poorly differentiated thyroid carcinoma; PTC, papillary thyroid carcinoma.
| Patients with positive PCT measurement
As summarized in Table 2 , positive PCT measurements (ie, ≥0.1 lg/L) were found in 9 of 2705 patients (0.33%). Of these, 7 (0.26%) showed concurrently positive serum CT (n = 7) with positive CT on FNAC washouts (n = 5) or stimulated CT measurements (n = 2), respectively. After surgery, MTC was histologically confirmed in all cases. None of them carried proto-oncogene RET mutations. Among the other 2 patients 1 had a symptomatic multinodular goitre with slightly positive PCT and basal CT levels at 0.16 lg/L and 11.6 ng/L and a negative stimulation test (ie, peak of CT: 56.8 ng/L), respectively. He was operated due to compressive symptoms with a benign histological report and no evidence of MTC. The second patient had an asymptomatic uninodular goitre with a slightly increased PCT at 0.11 lg/L. CT levels in serum and FNAC washouts were normal, and a benign cytological diagnosis was rendered after FNAC. As PCT levels spontaneously normalized after 1 month he was only assigned to periodical monitoring with unremarkable results over 4.5 years.
| Distribution of procalcitonin and calcitonin and ROC curve analysis
Procalcitonin and CT values obtained in patients operated with a definitive histological outcome of MTC (n = 7) were compared with those obtained in patients operated with a definitive histological exclusion of MTC (n = 371), respectively. Patients with MTC had significantly higher PCT levels (median 0.64 lg/L, range 0.16-12.9 lg/L) and CT levels (median 455 ng/L, range 37.5-3450 ng/L) than those with nonmedullary nodules (median 0.075 lg/L, range 0.075-0.16 lg/L and median 5 ng/L, range 5-73.2 ng/L, respectively; both P < .0001; Figure 1A ,B 
| DISCUSSION
Among 2705 patients with thyroid nodules a positive PCT detected 7 MTCs (0.26%). Basal serum CT levels were concordantly positive in these cases, and both markers were equally sensitive in detecting MTC among patients carrying thyroid nodules. In patients referred to surgery, thyroid tissues were intensively examined in macroscopical analysis with 0.5 cm serial sections and totally included in cassettes for histological and immunohistochemical examination when indicated. Although this intensive examination makes it unlikely, we cannot completely exclude the missing of small focal physiologic or preneoplastic C-cell hyperplasia (ie, more than 50 cells) or micromedullary thyroid carcinoma, due to the depth of our sections (grossly at 5 mm and subsequently on 5-7 lm histological slides). On the other hand, excepting multiple endocrine neoplasia syndromes and familial MTC (that were preliminarily excluded T A B L E 2 Clinical, biochemical and pathological data of patients with positive PCT measurement from the present study) the progression from C-cell hyperplasia to MTC and the progression or microscopic MTC to clinically overt disease is under question. 35 Indeed, the sensitivity and specificity of biomarkers testing should be based on the ability to diagnose clinically relevant MTC. In this setting, PCT and CT were equally sensitive in detecting MTC. However, among 378 patients with histologically confirmed MTC (n = 7) or nonmedullary outcome (n = 371), PCT and CT results were falsely positive in 2 (0.5%) and 19 (5%) patients, respectively. This is well in line with previous reports and confirms that PCT measurement could significantly reduce the need for confirmatory tests as CT measurement in FNAC washouts or stimulation test. In addition, PCT is less affected by analytical, physiological, pharmacological and pathological factors that can influence results of serum CT values and produce spurious hypercalcitoninemia. Finally, from the viewpoint of a routine clinical laboratory, it is more useful to implement the PCT assay which has a much wider range of indications than the CT assay. Notably, even if differently available PCT immunoassays produce consistent analytical result several studies have been carried out to evaluate the analytical performance and the possible implications on clinical classification of patients using different methods. 36 Overall, the published studies showed a satisfactory analytical alignment between BRAHMS PCT Kryptor and the other methods (r ≥ .9) with good agreements (>80%) in patient classification at the 3 conventional diagnostic thresholds for diagnosis of bacterial infections 0.50, 2.0 and 10 ng/mL, 37 but the unavoidable modest analytical bias between different IMAs suggests the use of the same method for longitudinal patient monitoring. In addition, no data on agreement between different methods are available in patients carrying thyroid nodules and MTC. As a consequence, the cut-off selected in our study should not be directly transferred to different assays, and patients' populations and proper evaluations by local laboratories are recommended.
In conclusion, our study proves that serum PCT measurement is a reliable and accurate alternative to CT as circulating tumour marker to screen patients carrying thyroid nodules for MTC.
